Introduction {#section5-1756283X18757715}
============

While observational studies have shown a role for macronutrients as risk factors for inflammatory bowel disease (IBD), fewer studies have investigated that of micronutrients.^[@bibr1-1756283X18757715][@bibr2-1756283X18757715][@bibr3-1756283X18757715]--[@bibr4-1756283X18757715]^ Nonetheless, it is well recognized that micronutrients have a relevant impact on different biological processes in IBD pathophysiology such as adaptive and innate immunity, and integrity of gastrointestinal barrier.^[@bibr1-1756283X18757715]^ Zinc is a micronutrient, which has been linked to inflammatory diseases such as IBD. Zinc deficiency (ZD) appears to compromise gastrointestinal barrier function, which can perpetuate different diseases such as celiac disease, chronic diarrhea or IBD.^[@bibr5-1756283X18757715]^ There are several pathways demonstrating how zinc or ZD may interact with these diseases. First, zinc plays a crucial role in the development and function of cells mediating innate immunity,^[@bibr6-1756283X18757715]^ has direct anti-inflammatory effects *via* zinc-finger protein A20,^[@bibr7-1756283X18757715]^ and has a positive effect on intestinal tight junctions^[@bibr8-1756283X18757715]^ and intestinal repair.^[@bibr9-1756283X18757715]^ Furthermore, zinc can act *via* metallothioneins (MTs). MTs are a family of small proteins with a high cysteine content at conserved positions that are rapidly upregulated in response to an inflammatory stimulus such as tumor necrosis factor (TNF).^[@bibr10-1756283X18757715]^ MT function seems to be dependent upon the presence of zinc.^[@bibr11-1756283X18757715]^ Effects of MTs include reduction of apoptosis^[@bibr12-1756283X18757715]^ and antimicrobial activity.^[@bibr13-1756283X18757715]^ Finally, zinc is critical for early and late autophagy.^[@bibr14-1756283X18757715]^ Autophagy is thought to suppress inflammation *via* degradation of inflammasomes and inflammasome-agonists.^[@bibr14-1756283X18757715]^ Genome-wide association studies revealed an association between a single nucleotide polymorphism in ATG16L1 -- a key player in autophagy -- and Crohn's disease (CD).^[@bibr15-1756283X18757715]^ In view of the latter, ZD might increase the impact of ATG16L1 polymorphisms.

Zinc deficiency is common in CD, with up to one third of all patients presenting with low serum zinc levels,^[@bibr16-1756283X18757715]^ even in patients in clinical remission.^[@bibr17-1756283X18757715]^ ZD in turn may exacerbate CD by increasing mucosal permeability, leading to neutrophil transmigration and luminal antigen permeation.^[@bibr18-1756283X18757715]^ Such increased mucosal permeability has been shown to correlate with both, CD activity^[@bibr19-1756283X18757715]^ and relapse probability.^[@bibr20-1756283X18757715]^ Despite high prevalence of ZD in IBD and its links to inflammation, so far no study investigated the role of serum zinc as a potential predictive serum marker for future disease course and its potential causative role in patients with a low or absent inflammatory disease activity.

Zinc levels have also been implicated in psychiatric disorders, where zinc is involved in several neurobiological and inflammation processes affecting mood.^[@bibr21-1756283X18757715][@bibr22-1756283X18757715]--[@bibr23-1756283X18757715]^ Increasing evidence suggest an association between low serum zinc levels and depression;^[@bibr23-1756283X18757715][@bibr24-1756283X18757715][@bibr25-1756283X18757715][@bibr26-1756283X18757715][@bibr27-1756283X18757715]--[@bibr28-1756283X18757715]^ however, whether this also applies to patients with IBD is, as yet, unknown. Scrutinizing the relationship of ZD with psychiatric symptomatology in IBD seems particularly important, as 24% and 37% of patients with CD have depression and anxiety, respectively, with these prevalence rates being almost twice as high in patients with active IBD.^[@bibr29-1756283X18757715]^ Both, depression and anxiety predict clinical recurrence in patients with CD^[@bibr30-1756283X18757715]^ and a bi-directional link between depressive mood and anxiety with the inflammatory response and disease course in IBD has been proposed.^[@bibr31-1756283X18757715]^ Particularly in the context of clinical disease remission, low serum zinc levels due to intestinal disease activity might be an important contributor to psychological symptoms in CD patients. Despite the high prevalence of both, ZD and symptoms of depression and anxiety in IBD patients, the impact of zinc levels and symptoms of depression or anxiety in IBD patients has not been explored. [Table 1](#table1-1756283X18757715){ref-type="table"} provides a summary of existing and new knowledge regarding zinc deficiency.

###### 

Summary of existing and new knowledge regarding zinc deficiency.

![](10.1177_1756283X18757715-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  What is known
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ZD is considered a common finding in CD with up to one third of all patients presenting with low serum zinc levels. ZD is found even in patients in clinical remission

  ZD may exacerbate CD activity, however long-term observational data are missing

  ZD interferes with early and late autophagy, while an ATG16L1 mutation, which is involved in autophagic processes, has been linked to CD

  ZD is associated with depression in non-CD patients. However, data on IBD patients are lacking, although up to 25% of CD patients have depression symptoms

  What is new

  In a cohort of 97 CD patients with disease remission, no single case of ZD has been identified

  Nonetheless, low-normal zinc levels were an independent predictor for the presence of depression symptoms in CD patients\

  Zinc levels at baseline did not predict complicated disease course, neither in CD patients overall nor ATG16L1^T300A^ carriers
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ZD, zinc deficiency; CD, Crohn's disease; IBD, inflammatory bowel disease.

We therefore aimed to assess the prevalence of ZD in CD patients in clinical remission and to analyze both a potential impact on future disease course as well as an interaction with mutations in ATG16L1. We further aimed to examine the association of zinc levels with symptoms of anxiety and depression.

Methods {#section6-1756283X18757715}
=======

Patients {#section7-1756283X18757715}
--------

The Swiss IBD cohort study (SIBDCS) is a nationwide cohort study from all regions of Switzerland, which has been including patients meeting the diagnostic criteria for IBD in accordance to established guidelines.^[@bibr32-1756283X18757715]^ Enrollment started in 2006. The SIBDCS is supported by the Swiss National Science Foundation and is approved by the local ethics committees of the participating centers (institutional review board no. EK-1316, approved on 5 February 2007). Written informed consent was obtained from all patients before enrollment into the study. Inclusion criteria for the SIBDCS have been published elsewhere.^[@bibr33-1756283X18757715]^ All CD patients currently enrolled in the SIBDCS were screened for eligibility. For this study, only CD patients with a minimum follow-up period of 1 year were selected. In order to analyze the impact of zinc on future disease course, only patients with disease remission at baseline were selected based on a Crohn's Disease Activity Index (CDAI) ≤ 150 and absent endoscopic or histological disease activity (if endoscopy and histological examinations were performed). Further inclusion criteria were: (a) age ⩾ 18 years, (b) documented evidence/presence of CD prior to cohort enrollment, and (c) either complicated or uncomplicated disease course during the follow-up period (1:1 ratio) according to the definition below. Exclusion criteria were: (a) documented evidence/presence of ulcerative colitis (UC), (b) evident inflammatory disease activity (one of the following) \[CDAI \> 150, active endoscopic disease activity (if applicable), histologic findings of chronic or acute inflammation on biopsies (if applicable), active clinical disease course\], (c) any zinc supplementation products at baseline or during the follow-up period. Patients were selected for further analyses and serum zinc testing, aimed at obtaining roughly equal fractions of patients with *versus* without future complicated disease course (as defined below) within the follow-up period (roughly 1:1 ratio). A sample size of 44 patients in each group would detect a difference in serum zinc levels of 1.5 μmol/l between CD without complicated disease course and CD with a future complicated disease course with a power of 80% (alpha error 0.05, standard deviation 2.5 μmol/l). A standard deviation of 2.5 μmol/l was chosen based on a recent publication by Beckett and colleagues.^[@bibr34-1756283X18757715]^ In another study regarding serum zinc levels in CD and UC, standard deviation ranged from 1.9 to 2.1 μmol/l.^[@bibr16-1756283X18757715]^

Definitions {#section8-1756283X18757715}
-----------

Future complicated disease course was defined as any one of the following: (a) flare up or (b) need for new anti-TNF, or (c) development of stenosis, abscess, fistula or anal fissure, adapted from previously suggested criteria.^[@bibr35-1756283X18757715]^ Uncomplicated disease course was defined as the absence of all the abovementioned criteria for complication and a CDAI of \<220. Zinc deficiency was defined as serum levels of less than 11 μmol/l (normal range 11--24 μmol/l).^[@bibr36-1756283X18757715]^ Low--normal zinc values were defined as below the 30th percentile of the normal range. For simplification, this cut-off (14.9) was rounded up in order to consider the range 11--15 μmol/l as low--normal.

Data collection {#section9-1756283X18757715}
---------------

All clinical data were available from the SIBDCS. Zinc was measured from serum tubes stored at −70°C. Analysis was performed by a commercial laboratory (Unilabs, Coppet VD, Switzerland) using ion-coupled-plasma-mass spectroscopy (ICP-MS Varian 820). To rule out the possibility of factitious zinc contamination of serum samples due to long-term frozen sample storage in conventional serum tubes, a pilot study was conducted with 10 random serum samples from the SIBDCS data center (see results section). The following clinical variables were collected from the SIBDCS: patient demographics (age at enrollment, sex, BMI, smoking status), baseline disease characteristics and activity (stool frequency, CDAI, disease localization, date of first symptoms, date of diagnosis, diagnostic delay, past and current treatments), follow-up disease characteristics and activity (CDAI, past and current medications, complications, stool frequency, flares) and genetic data regarding single nucleotide polymorphism (SNP) rs2241880 (ATG16L1 gene variant).^[@bibr15-1756283X18757715]^ The ATG16L1 polymorphism occurs in three isoforms: homozygous wild-type (AA), heterozygous (AG) and homozygous variant (GG).^[@bibr37-1756283X18757715]^ Depression and anxiety symptoms were measured in the SIBDCS at baseline and during the follow-up period according to Zigmond and Snaith; The Hospital Anxiety and Depression Scale (HADS) is a self-assessment mood scale developed for outpatients comprising 14 questions graded on a 4-point Likert scale with subscales of anxiety and depression (total score 0--21, while 0--7 were considered normal, 8--10 indicative of mild, 11--14 indicative of moderate, and 15--21 indicative of severe anxiety/depression).^[@bibr38-1756283X18757715]^

Statistical analysis {#section10-1756283X18757715}
--------------------

For statistical analysis, the IBM Software SPSS Statistics Version 22.0.0 (2013, SPSS Science, Inc., Chicago, IL) was used. Complete data were analyzed in a pooled manner, with further separate consecutive analysis for patients with a future complicated *versus* a future uncomplicated disease course. Categorical data are depicted as percentage of the group total. For comparisons between continuous variables, two-sample *t* test and Mann--Whitney *U* test were used depending on whether data were normally distributed or not. Comparison between categorical data was performed with the Chi-square test. For correlation studies investigating the influence of zinc levels on stool frequency and anxiety/depression symptoms, the Pearson and Spearman tests were used, respectively. Multivariate logistic regression regarding prediction of low zinc levels for future CD outcome and for presence of depression symptoms was performed by first taking into account all covariates with a univariate *p* value of \<0.15, removing insignificant covariates, and then adding remaining covariates one by one, checking the model significance and consistency at each step. For the purposes of this study, a *p* value of \<0.05 was considered statistically significant.

Results {#section11-1756283X18757715}
=======

Patient demographics {#section12-1756283X18757715}
--------------------

A total of 97 patients, 50 with a complicated and 47 with an uncomplicated future disease course, were analyzed. Mean age was 40.4 years (±15.7); 43 were males (44.3%). Median duration of CD at baseline was 6.6 years \[interquartile range (IQR) 2.6--15.6 years\]. All patients were in clinical remission at study enrollment with a median CDAI at baseline of 34.0 (IQR 11.0--53.0). A sum of 26 patients (26.8%) were current smokers. Mean BMI was 23.9 kg/m^2^ (±4.2 kg/m^2^). According to the Montreal classification, 36 patients had ileal disease (L1, 37.1%), while 23 had colonic (L2, 23.7%) and 31 had ileocolonic (L3, 32.0%) disease at baseline. In four patients (4.1%), isolated upper gastrointestinal tract disease (L4) was reported. Four patients with ileal and colonic disease had additional upper gastrointestinal tract involvement (one patient with L1 and three patients with L2). In three patients, Montreal classification was not applicable. Median diagnostic delay (time from first symptoms to diagnosis) was 7.5 months (IQR 1.0--27.5 months). No prior or current anti-tumor necrosis factor (TNF) treatment was reported. None of the patients received any zinc supplementation products. Median frequency of liquid stools (per week) at baseline was 0 (IQR 0--14). Although all patients were in clinical remission at baseline, patients with a future complicated disease course had higher CDAI scores (but still ⩽150) and reported longer CD duration than patients who did not experience complications in the follow-up period. Otherwise, no differences were seen between the two groups at baseline evaluation, including in psychiatric symptoms. For a detailed synopsis over the whole study population and a comparison between group 1 (complicated future disease course) and group 2 (uncomplicated future disease course), see [Table 2](#table2-1756283X18757715){ref-type="table"}.

###### 

Baseline patient and disease characteristics.

![](10.1177_1756283X18757715-table2)

                                                       All patients (*n* = 97)   Complicated future disease course (*n* = 50)                               Uncomplicated future disease course (*n* = 47)
  ---------------------------------------------------- ------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------
  Age in years, mean (SD)                              40.4 (15.7)               43.2 (15.1)                                                                37.5 (15.9)
  Sex                                                                                                                                                       
   − Male                                              43 (44.3%)                22 (44.0%)                                                                 21 (44.7%)
   − Female                                            54 (55.7%)                28 (56.0%)                                                                 26 (55.3%)
  BMI in kg/m^2^, mean (SD)                            23.9 (4.2)                24.2 (4.7)                                                                 23.5 (3.5)
  Duration of CD at enrolment in years, median (IQR)   6.6 (2.6--15.6)           9.0 (3.7--21.0)                                                            4.2 (1.1--14.3)^[a](#table-fn2-1756283X18757715){ref-type="table-fn"}^
  Diagnostic delay in months, median (IQR)             7.5 (1.0--27.5)           8.0 (1.0--24.5)                                                            7.0 (2.0--36.0)
  Current smoking status                                                                                                                                    
   − Yes                                               26 (26.8%)                12 (24.0%)                                                                 14 (29.8%)
   − No                                                55 (56.7%)                26 (52.0%)                                                                 29 (61.7%)
   − Missing                                           16 (16.5%)                12 (24.0%)                                                                 6 (8.5%)
  Past IM                                                                                                                                                   
   − Yes                                               16 (16.5%)                10 (20.0%)                                                                 6 (12.8%)
   − No                                                81 (83.5%)                40 (80.0%)                                                                 41 (87.2%)
  Anti-TNF naïve                                                                                                                                            
   − Yes                                               97 (100%)                 50 (100%)                                                                  47(100%)
   − No                                                0                         0                                                                          0
  Current treatment                                                                                                                                         
   − 5-ASA                                             20 (20.6%)                9 (18.0%)                                                                  11 (23.4%)
   − AZA/6-MP                                          43 (44.3%)                26 (52.0%)                                                                 17 (36.2%)
   − Topical steroids                                  27 (27.8%)                14 (28.0%)                                                                 13 (27.7%)
   − MTX                                               5 (5.2%)                  2 (4.0%)                                                                   3 (6.4%)
   − None                                              19 (19.6%)                7 (14.0%)                                                                  12 (25.5%)
  Disease localization                                                                                                                                      
   − L1                                                36 (37.1%)                17 (34.0%)                                                                 19 (40.4%)
   − L2                                                23 (23.7%)                12 (24.0%)                                                                 11 (23.4%)
   − L3                                                31 (32.0%)                18 (36.0%)                                                                 13 (27.7%)
   − L4                                                4 (4.1%)                  2 (4.0%)                                                                   2 (4.3%)
   − Missing                                           3 (3.1%)                  1 (2.0%)                                                                   2 (4.3%)
  CDAI, median (IQR)                                   34.0 (11.0--53.0)         38.0 (22.3--53.8)^[a](#table-fn2-1756283X18757715){ref-type="table-fn"}^   21.0 (6.0--42.5)^[b](#table-fn3-1756283X18757715){ref-type="table-fn"}^
  Number of liquid stools per week, median (IQR)       0.0 (0.0--14.0)           1.0 (0.0--14.0)                                                            0.0 (0.0--7.0)
  HADS anxiety score, median (IQR)                     6 (3--9)                  6 (4--9)                                                                   5.5 (2.25--8)
  HADS depression score, median (IQR)                  3 (1--6)                  4 (2--6)                                                                   2.5 (0--5)
  Follow up                                                                                                                                                 
   − 1y                                                12 (12.4%)                2 (4.0%)                                                                   10 (21.3%)
   − 2y                                                15 (15.5%)                6 (12.0%)                                                                  9 (19.1%)
   − 3y or +                                           70 (72.2%)                42 (84.0%)                                                                 28 (59.6%)^[c](#table-fn4-1756283X18757715){ref-type="table-fn"}^

Duration of CD at enrollment was significantly longer in group 1 (future complicated disease course) compared with group 2 (uncomplicated disease course), *p* = 0.018.

CDAI at baseline was significantly higher in group 1 compared with group 2, *p* = 0.014.

A 3 years or more follow up was reported more often in group 1 compared with group 2, *p* = 0.009.

SD, standard deviation; CD, Crohn's disease; BMI, body mass index; TNF, tumor necrosis factor; IQR, interquartile range; IM, Immunomodulation; HADS, Hospital Anxiety and Depression Scale; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; MTX, methotrexate; L1, Montreal classification ileal disease; L2, Montreal classification colonic disease; L3, Montreal classification ileocolonic disease; L4, Montreal classification isolated upper gastrointestinal tract disease; CDAI, Crohn's disease activity index.

Zinc pilot analysis {#section13-1756283X18757715}
-------------------

Given the fact that special trace element free tubes are frequently used for zinc analysis, because of possible interference of minimal amounts of trace elements in the serum tube itself, we first conducted a pilot study to evaluate accuracy of zinc analysis from 10 random serum samples stored at the SIBDCS datacenter. Results from those samples are depicted in [Supplementary Figure 1](http://journals.sagepub.com/doi/suppl/10.1177/1756283X18757715). Mean zinc level was 11.8 μmol/l with a median of 11.8 μmol/l and a total range of 6.5--16 μmol/l. In eight samples, zinc level was within the normal range, which is 11--24 μmol/l, while the remaining two samples (20%) showed reduced zinc levels. None of the samples showed an elevated zinc level. Accordingly, measuring zinc from normal serum tubes did not induce false-high results and indeed, reflected adequate levels within an anticipated range.

Zinc levels {#section14-1756283X18757715}
-----------

Mean zinc level in the study population was 18.0 ± 4.7 μmol/l. No absolute ZD (defined as \<11 μmol/l) was observed. Low zinc levels (defined as \<15.1 μmol/l) were found in 28 patients (28.9%). Males had significantly higher zinc levels compared with females (19.4 ± 5.7 μmol/l *versus* 16.8 ± 3.3 μmol/l, *p* = 0.006), and the proportion of patients with low zinc levels was higher among females (20/54, 37.0% *versus* 8/43, 18.6%, *p* = 0.047). Patients with a longer diagnostic delay (\>23.9 months) showed a trend towards higher proportion of low zinc levels (11/26, 42.3% *versus* 12/42, 22.2%, *p* = 0.063). Patients with more than seven liquid stools per week (*n* = 29) more frequently had low serum zinc levels (13/29, 44.8%) compared with patients with seven or less liquid stools (15/62, 24.2%, *p* = 0.047). For details, see [Figure 1](#fig1-1756283X18757715){ref-type="fig"}. However, serum zinc levels did not significantly correlate with number of liquid stools at baseline (rho --0.113, *p* = 0.285). In a univariate regression model, female sex, stool frequency, diagnostic delay and immunosuppression at baseline were relevant predictors for low serum zinc levels (*p* \< 0.15). When those factors were analyzed in a multivariate regression model, immunosuppression remained the only significant predictor, while stool frequency showed at least a trend towards statistical significance. For univariate and multivariate analyses, see [Table 3](#table3-1756283X18757715){ref-type="table"}.

![Proportion of patients with low serum zinc level according to sex, stool frequency, diagnostic delay, presence of depression symptoms and presence of ATG16L1 risk variants.](10.1177_1756283X18757715-fig1){#fig1-1756283X18757715}

###### 

Regression model for prediction of low serum zinc levels.
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  Variable               Category             *n* = 97   Low serum zinc levels (%)   Single predictor model     Multiple predictor model                              
  ---------------------- -------------------- ---------- --------------------------- -------------------------- -------------------------- -------------------------- -----------
  Age                                                                                1.001 (0.973--1.029)       0.949                                                 
  Sex                    Male                 43         8 (18.6%)                   **0.389 (0.151--1.001)**   **0.05**                   0.412 (0.131--1.296)       0.129
                         Female               54         20 (37.0%)                  1                                                     1                          
  BMI                                                                                1.048 (0.944--1.164)       0.377                                                 
  Current smoker         Nonsmoker            55         15 (27.3%)                  0.844 (0.303--2.346)       0.745                                                 
                         Smoker               26         8 (30.8%)                   1                                                                                
  High stool frequency   7 stools or less     62         15 (24.25)                  **0.393 (0.154--1.000)**   **0.05**                   0.358 (0.117--1.097)       0.072
                         More than 7 stools   29         13 (44.8%)                  1                                                     1                          
  Ileal disease          Not L1               58         16 (27.6%)                  0.866 (0.347--2.158)       0.757)                                                
                         L1                   36         11 (30.6%)                  1                                                                                
  Diagnostic delay       \<24 months          42         12 (22.2%)                  **0.390 (0.142--1.068)**   **0.067**                  0.420 (0.142-1.249)        0.119
                         \>23.9 months        26         11 (42.3%)                  1                                                     1                          
  Past IM treatment      No                   81         21 (25.9%)                  0.450 (0.149--1.360)       0.157                                                 
                         Yes                  16         7 (43.8%)                   1                                                                                
  Current IM treatment   No                   47         9 (19.1%)                   **0.386 (0.153--0.974)**   **0.044**                  **0.280 (0.089--0.879)**   **0.029**
                         Yes                  50         19 (38.0%)                  1                                                     1                          
  CDAI                                                                               1.003 (0.990--1.017)       0.656                                                 
  SNP risk variant       No                   36         11 (30.6%)                  0.660 (0.227--1.923)       0.446                                                 
                         Yes                  25         10 (40.0%)                  1                                                                                

OR, odds ratio; CI, confidence interval; BMI, body mass index; L1, Montreal classification ileal disease; IM, Immunomodulation; CDAI, Crohn's disease activity index; SNP, single nucleotide polymorphism. significant results are in bold font.

Anxiety and depression symptoms {#section15-1756283X18757715}
-------------------------------

A total of 27 of the 97 patients (27.8%) reported at least mild anxiety symptoms at baseline evaluation (including 9 patients with moderate and 1 with severe anxiety). Median HADS anxiety score was 6 (IQR 3--9). Depression symptoms were reported by 11 of the 97 patients (11.3%): seven patients had mild, four had moderate, and none had severe depression at baseline. Median HADS depression score was 3 (IQR 1--6). Zinc levels and anxiety score did not show any correlation, nor did zinc levels and classification into normal, mild, moderate and severe anxiety. However, we found a mild, but significant correlation between zinc levels and severity of depression (rho --0.277, *p* = 0.016). Patients with low serum zinc levels significantly more often reported depression symptoms compared with patients with higher serum zinc levels (6/22, 27.3% *versus* 5/53, 9.4%, *p* = 0.047). In a multivariate regression model corrected for stool frequency and CDAI, zinc levels at baseline were an independent negative predictor for the presence of depression symptoms \[odds ratio (OR) 0.727, 95% confidence interval (CI) 0.532--0.993, *p* = 0.045\]. For details see [Table 4](#table4-1756283X18757715){ref-type="table"}.

###### 

Regression model for prediction of depression symptoms.

![](10.1177_1756283X18757715-table4)

  Variable                   Category             *n* = 75^[\*](#table-fn7-1756283X18757715){ref-type="table-fn"}^   Depression symptoms (%)   Single predictor model     Multiple predictor model                              
  -------------------------- -------------------- ------------------------------------------------------------------ ------------------------- -------------------------- -------------------------- -------------------------- -----------
  Age                                                                                                                                          **1.001 (0.962--1.042)**   **0.952**                                             
  Sex                        Male                 32                                                                 4 (12.5%)                 0.735 (0.195--2.761)       0.648                                                 
                             Female               43                                                                 7 (16.3%)                 1                                                                                
  BMI                                                                                                                                          1.036 (0.885--1.212        0.661                                                 
  Current smoker             Nonsmoker            41                                                                 6 (14.6%)                 1.457 (0.266--7.992)       0.665                                                 
                             Smoker               19                                                                 2 (10.5%)                 1                                                                                
  High stool frequency       7 stools or less     48                                                                 4 (8.3%)                  **0.258 (0.065--1.027)**   **0.055**                  0.397 (0.051--3.089)       0.377
                             More than 7 stools   23                                                                 6 (26.1%)                 1                                                     1                          
  Diagnostic delay           \<24 months          43                                                                 5 (11.6%)                 0.526 (0.125--2.219)       0.382                                                 
                             \>23.9 months        20                                                                 4 (20.0%)                 1                                                                                
  IM treatment at baseline   No                   37                                                                 4 (10.8%)                 0.537 (0.143--2.015)       0.357                                                 
                             Yes                  38                                                                 7 (18.4%)                 1                                                                                
  CDAI                                                                                                                                         **1.017 (0.998--1.037)**   **0.076**                  1.009 (0.978--1.041)       0.559
  SNP risk variant           Yes                  24                                                                 3 (12.5%)                 0.607 (0.119--3.092)       0.548                                                 
                             No                   21                                                                 4 (19.0%)                 **1**                                                                            
  Zinc levels                                                                                                                                  **0.742 (0.562--0.981)**   **0.036**                  **0.727 (0.532--0.993)**   **0.045**

Data on presence or absence of depressive symptoms were available for 75 patients.

OR, odds ratio; CI, confidence interval; BMI, body mass index; IM, Immunomodulation; CDAI, Crohn's disease activity index; SNP, single nucleotide polymorphism. significant results are in bold font.

Single nucleotide polymorphism analysis {#section16-1756283X18757715}
---------------------------------------

ATG16L1 SNP analysis was available from 61 patients (62.9%) with 25 (25/61, 41.0%) being homozygous for the risk variant rs2241880 (T300A), while 23 patients were heterozygotes. Zinc levels of patients with ATG16L1^T300A^ (homozygotes) did not differ from those of patients without or with only one risk allele (16.3 ± 2.7 μmol/l *versus* 17.1 ± 3.2 μmol/l, n.s.). In addition, the proportion of low serum zinc levels did not show any significant differences between the two groups: low zinc levels were found in 10 out of the 25 patients carrying the risk variant and in 11 out of the 36 patients without the risk variant (40.0% *versus* 30.6%, n.s). In a regression model, presence of ATG16L1^T300A^ did not predict low serum zinc levels. For details, see [Table 3](#table3-1756283X18757715){ref-type="table"}.

Prediction of future complicated disease course {#section17-1756283X18757715}
-----------------------------------------------

Patients were followed for 1 (12, 12.4%), 2 (15, 15.5%) or 3 years and longer (70, 72.2%). The following complications occurred: 29 patients (29/50, 58.0%) experienced a flare up, 26 patients (26/50, 52.0%) needed new anti-TNF treatment, and 45 patients (45/50, 90.0%) developed stenosis, abscess, fistula or anal fissure. Zinc levels of patients with a future complicated disease course were not different from those of patients without complications (17.7 ± 4.3 μmol/l *versus* 18.3 ± 5.1 μmol/l, n.s.). Proportions of patients with low serum zinc levels were comparable with 16 out of 50 (32.0%) in the complicated disease group and 12 out of 47 (25.5%) in the uncomplicated disease group (n.s.). We did not observe any differences when females/males were analyzed separately. Looking only at ATG16L1^T300A^ carriers, no difference in zinc levels between patients with *versus* without a complicated disease course was seen (16.0 ± 2.6 μmol/l *versus* 17.3 ± 2.9 μmol/l, n.s). After screening the potential predictors for future disease outcome one by one, the variables age, CDAI at baseline, stool frequency and presence of ATG16L1^T300A^ were retained in the multiple predictor model in addition to serum zinc levels (see [Table 5](#table5-1756283X18757715){ref-type="table"}). Presence of ATG16L1^T300A^ seemed to be the only predictive variable, although statistical significance was not achieved (*p* = 0.053). Nevertheless, neither absolute zinc levels at baseline nor presence of low serum zinc levels (\<15.1 μmol/l) predicted future complicated disease course.

###### 

Regression model for prediction of future complicated disease outcome.

![](10.1177_1756283X18757715-table5)

  Variable                   Category             *n* = 97   Complicated disease course (%)   Single predictor model     Multiple predictor model                           
  -------------------------- -------------------- ---------- -------------------------------- -------------------------- -------------------------- ----------------------- -------
  Age                                                                                         **1.025 (0.998--1.052**    **0.076**                  1.009 (0.971--1.048)    0.641
  Sex                        Male                 43         22 (51.2%)                       0.973 (0.436--2.168)       0.946                                              
                             Female               54         28 (51.9%)                       1                                                                             
  BMI                                                                                         1.046 (0.946--1.156)       0.382                                              
  Current smoker             Nonsmoker            55         26 (47.3%)                       1.046 (0.411--2.665)       0.925                                              
                             Smoker               26         12 (46.2%)                       1                                                                             
  High stool frequency       7 stools or less     62         30 (48.4%)                       **0.493 (0.198--1.23)**    **0.130**                  0.545 (0.107--2.772)    0.464
                             More than 7 stools   29         19 (65.5%)                       1                                                     1                       
  Ileal disease              Not L1               58         32 (55.2%)                       1.376 (0.597--3.168)       0.454                                              
                             L1                   36         17 (47.2%)                       1                                                                             
  Diagnostic delay           \<24 months          54         28 (51.9%)                       1.469 (0.572--3.773)       0.425                                              
                             \>23.9 months        26         11 (42.3%)                       1                                                                             
  IM treatment at baseline   No                   47         21 (44.7%)                       0.585 (0.262--1.307)       0.191                                              
                             Yes                  50         29 (58.0%)                       1                                                                             
  CDAI                                                                                        **1.016 (1.002--1.031)**   **0.028**                  1.004 (0.978--1.030)    0.776
  SNP risk variant           Yes                  25         19 (76.0%)                       **3.167 (1.026--9.77)**    **0.045**                  3.479 (0.983--12.312)   0.053
                             No                   36         18 (50.0%)                       **1**                                                                         
  Zinc levels                                                                                 0.968 (0.887--1.058)       0.476                      0.956 (0.786--1.162)    0.649
  Low serum zinc             No                   69         34 (49.3%)                       0.729 (0.301--1.765)       0.483                                              
                             Yes                  28         16 (57.1%)                       1                                                                             

OR, odds ratio; CI, confidence interval; BMI, body mass index; L1, Montreal classification ileal disease; IM, Immunomodulation; CDAI, Crohn's disease activity index; SNP, single nucleotide polymorphism. significant results are in bold font.

Discussion {#section18-1756283X18757715}
==========

This analysis of prospectively obtained data from a nationwide cohort study in Switzerland tested for an association of serum zinc levels and psychiatric symptoms, stool frequency and future disease course in CD patients in clinical remission at baseline. In our subset of SIBDCS patients with CD in clinical remission, we did not observe ZD. However, zinc levels revealed to be low--normal in a considerable proportion of patients. Zinc levels were lower among females when compared with their male counterparts as well as among those patients with more than seven liquid stools per week. Intriguingly, lower zinc levels were an independent predictor for depression, but not anxiety symptoms. Zinc levels at baseline did not predict complicated disease course, neither in CD patients overall nor ATG16L1^T300A^ carriers. Yet, in the latter, we observed a clear albeit nonsignificant trend towards an increase in complications in both univariate and multivariate testing.

In contrast to the studies conducted by Vagianos and colleagues^[@bibr16-1756283X18757715]^ and Filippi and colleagues,^[@bibr17-1756283X18757715]^ who reported zinc deficiency in up to 65% even in patients with clinical remission, we did not identify a single case with serum zinc levels below the reference value of 11μmol/l. When we compare our demographic data with that of Filippi and colleagues, our patients had lower CDAI (mean 37.5 *versus* 89.7) and did not report any previous CD-related surgery, while nearly 50% of the patients studied by Filippi and colleagues had undergone ileal, ileocecal or colonic resection.^[@bibr17-1756283X18757715]^ Therefore, presence of ZD may have been overestimated by previous studies not exclusively considering CD patients in remission. Data on the impact of sex on serum zinc levels are conflicting; in contrast to other micronutrient studies, but in accordance to findings from the National Health and Nutrition Examination Survey study, we found significant sex-specific differences, with lower zinc levels among females.^[@bibr39-1756283X18757715][@bibr40-1756283X18757715][@bibr41-1756283X18757715]--[@bibr42-1756283X18757715]^ This is particularly noteworthy, as it has been previously described that daily intake of zinc (assessed with the use of prospective food records for three days) was higher among females compared with males, which may not be the case in our cohort.^[@bibr17-1756283X18757715]^ However, influence of sex on zinc levels may be biased by several confounders such as stool frequency, diagnostic delay and immunosuppressive therapy, as in a multivariate regression model corrected for those variables, sex was not an independent predictor for low serum zinc levels. Accordingly, our results should be replicated in a larger IBD study population.

The proportion of patients with low serum zinc levels tended to be higher among patients with more than seven liquid stools per week. Thus, low serum zinc may be a promotor of diarrhea or higher stool frequency in the presence of clinical and endoscopic disease remission. This finding is supported by prior studies demonstrating increased gut permeability in the context of zinc deficiency and by studies testing zinc supplementation for treatment of acute diarrhea.^[@bibr18-1756283X18757715],[@bibr43-1756283X18757715][@bibr44-1756283X18757715]--[@bibr45-1756283X18757715]^ Therapeutic effects of zinc might be attributable to reduction of a transmucosal leak and to a K-channel blockage of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion.^[@bibr43-1756283X18757715],[@bibr46-1756283X18757715]^ Therefore, even in the absence of absolute zinc deficiency, low zinc levels might be clinically relevant, promoting diarrhea and elevated stool frequency. However, the opposite might also be the case: increased frequency of liquid stools leads to a decrease in serum zinc levels. More clinical data is needed to assess direction of this association and in order to generate clear recommendations regarding zinc supplementation in CD patients with low--normal zinc levels.

In our study, the ATG16L1 risk variant was an independent risk factor for future CD outcome, bordering significance in the multivariate analysis, which contrasts the finding from Cleynen and colleagues which could not show any association of risk gene variants and disease outcome.^[@bibr47-1756283X18757715]^ However, low serum zinc levels did not have a different effect on stool frequency or disease outcome when comparing those patients harboring the risk variant *versus* those that did not. Thus, the hypothesis that zinc deficiency or low zinc levels might increase the impact of ATG16L1 could not be supported. One explanation might be that a mutated ATG16L1 disrupts autophagy to an extent, that any potential additional effect of low zinc becomes negligible.

Several epidemiological and animal studies have shown an association between low serum zinc levels and depression symptoms.^[@bibr23-1756283X18757715][@bibr24-1756283X18757715][@bibr25-1756283X18757715][@bibr26-1756283X18757715][@bibr27-1756283X18757715]--[@bibr28-1756283X18757715],[@bibr48-1756283X18757715],[@bibr49-1756283X18757715]^ In addition, at least some evidence for zinc supplementation can be derived from randomized controlled-trials with patients in clinical depression.^[@bibr50-1756283X18757715],[@bibr51-1756283X18757715]^ However, until now, to the best of our knowledge, no study has linked serum zinc levels and depression symptoms in patients with IBD. In a multivariate regression model correcting for relevant confounders such as CDAI or stool frequency, we were able to show that low serum zinc levels are an independent predictor for depression symptoms. This is noteworthy, given a previous study from the Swiss IBD cohort showing that depression is associated with higher rates of clinical recurrence of IBD.^[@bibr30-1756283X18757715]^ Considering that we evaluated patients in clinical remission only and none of those had absolute zinc deficiency, the inverse effect of zinc on psychiatric symptoms might be even stronger in a larger population with more severe and active disease and further studies are warranted. In fact, the percentage of patients in the current study with clinically relevant (i.e. at least mild) symptoms of depression (11%) or anxiety (28%) was only half of the level expected from recent meta-analytic data.^[@bibr29-1756283X18757715]^ This low level of psychological distress could also be an explanation for the lack of an association between anxiety and zinc level in our patients. To compare, lower serum zinc levels were significantly associated with more severe anxiety symptoms in female students from Iran, of whom 66% had at least mild anxiety measured with the HADS.^[@bibr52-1756283X18757715]^ Also, a series of carefully conducted animal studies imply a role of zinc deficiency in anxiety-like behaviors.^[@bibr53-1756283X18757715]^

It is advocated that patients with IBD should be screened for psychological comorbidities, including depressive symptoms, and psychological support should be a part of standard care for those in need.^[@bibr54-1756283X18757715]^ However, whether zinc levels in CD patients with relevant depressive symptoms should be tested to start supplementation therapy in case of nutritional deficiency has yet to be determined. Currently available evidence as to whether zinc supplementation alleviates depressive symptoms in humans (without IBD) is scarce and conflicting.^[@bibr22-1756283X18757715]^ Nonetheless, our findings provide a rationale for zinc supplementation in CD patients with depressive symptoms, potentially even in patients with low--normal serum zinc levels.

Our study has several strengths and some limitations. We provide the first study evaluating an association of serum zinc levels and psychiatric symptoms in CD patients. In addition, it is the first analysis that evaluates the effect of zinc levels on future disease course with regards to the presence or absence of the ATG16L1 risk variant, therefore linking epidemiological observations with molecular disease mechanisms. The SIBDCS is a large and well-established cohort with structured annual physician- and patient-based assessments. However, albeit the prospective nature of data acquisition, retrospective analysis with annual follow-up visits only may be associated with underreporting of symptoms in general and psychiatric symptoms in particular. A limitation of our study is that significantly more patients in the future complicated disease group had a follow up of 3+ years compared with those not experiencing any complications, which might lead to underreporting of late complications in the uncomplicated disease course group. However, as we only took into account the first complication (being sufficient to fall into the complication category), we feel rather confident to assume the two groups and their follow up to be comparable. Our study might be underpowered to detect weaker effects of ZD on disease course. The role of zinc may have been underestimated, since all patients were in clinical remission at baseline without frank zinc deficiency. Although all patients were in clinical remission at baseline, patients with a future complicated disease course had higher CDAI values at first visit and reported a longer CD duration. This slightly, but significantly higher clinical disease activity and the longer disease duration might be considerable confounders of our analysis. And finally, zinc levels were only measured at baseline, but not during follow up and during flares, although, presumably, these levels are prone to fluctuations, which should be taken into account in future studies.

Taken together, zinc deficiency in CD patients with clinical remission did not seem to be as relevant as previously thought based on the rather sparse literature. However, low serum zinc levels were an independent predictor for presence of depression symptoms. Whether supplementation can be recommended in those patients in general has to be determined in the future. In the absence of active disease, low zinc levels did not predict complicated disease course regardless of ATG16L1 genotype.
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